**Specifications Table**TableSubject area*Pharmaceutical Sciences*More specific subject area*Bioavailability and Bioequivalence*Type of data*Table*How data was acquired*High performance liquid chromatography with ultraviolet detection*Data format*Raw*Experimental factors*Blood plasma samples were processed for efavirenz extraction and quantification as described elsewhere*[@bib1]Experimental features*A 2-treatment, 2-period, 2-sequence, randomized and balanced crossover design was carried out with 14 healthy subjects, 8 women and 6 men*Data source location*Montevideo, Uruguay*Data accessibility*Data supplied with this article*

**Value of the data**•Efavirenz pharmacokinetic data with intensive sampling obtained after nightly dosing. Characterization of efavirenz pharmacokinetics after single oral nightly dose can be performed with this data. Efavirenz chronopharmacokinetics and evaluation of daytime administration on bioequivalence can be studied by comparison with standard bioequivalence trials.•Comparison of Reference (Stocrin®, Merck Sharp & Dohme) performance in different populations. Data collected for the Reference formulation could be managed with the objective of comparing its performance in different populations.•Development of in vitro--in vivo correlations. Efavirenz is classified as Class II drug in the Biopharmaceutical Classification System (BCS), its oral absorption is limited by its dissolution. Appropriate in vitro assays could help to explain and predict dosage bioavailability.

1. Data {#s0005}
=======

In this article, raw pharmacokinetic data obtained in an efavirenz average bioequivalence study carried out on 14 healthy subjects is presented. Venous plasma efavirenz concentrations were obtained after a 600 mg oral dose of a local brand (Test) and the Reference, Stocrin (Merck Sharp & Dohme).

2. Experimental design, materials and methods {#s0010}
=============================================

A randomized two-treatment, two-period, two-sequence, single-dose crossover study with a washout period of 28 days was performed for bioequivalence evaluation of Test formulation. Sixteen healthy Caucasian subjects were initially recruited, 8 males and 8 females. Dose (600 mg) was administered at night (9:00 p.m.) two hours after the intake of a standardized dinner. Blood samples were obtained up to 96 h post-dosing. Efavirenz concentrations were measured in venous plasma by high performance liquid chromatography with UV detection at 205 nm (HPLC-UV), using a validated analytical method with a lower limit of quantification of 50 ng/mL. Detailed information regarding this method was previously described [@bib1]. The study protocol followed the tenets of the Declaration of Helsinki adopted by the World Medical Association in 1964 and its successive amendments, being previously approved by the Institutional Ethics Review Committee of the Faculty of Chemistry -- Universidad de la República. All volunteers received a leaflet with study details and efavirenz information and signed a consent form before their entry to the study. [Table 1](#t0005){ref-type="table"} summarizes the demographic characteristics of participating volunteers, along with the assigned sequence of product administration. Fourteen volunteers finished the study. Subject 16 did not show up the first day of the study. Subject 11 presented rash after administration of Test formulation. Fortunately, both individuals belonged to different sequence of administration, and so replacement was not necessary to maintain the crossover balanced.

Pharmacokinetic data of efavirenz after single oral dose of Test and Reference is presented in [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}. For subject 11, only Test data is available. Individual efavirenz plasma concentration from both formulations could be retrieved from a previously published article [@bib2].

Appendix A. Supplementary material {#s0020}
==================================

Supplementary material

In vivo data was taken from a study funded by Servimedic Laboratory, Uruguay.

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2016.03.036](http://dx.doi.org/10.1016/j.dib.2016.03.036){#ir0005}.

![Individual efavirenz plasma concentration--time profiles after the administration of Test and Reference formulations.](gr1){#f0005}

![Individual efavirenz plasma concentration--time profiles (log-linear scale) after the administration of Test and Reference formulations.](gr2){#f0010}

###### 

Subject demographic characteristics.

Table 1

  **Subject IDS**   **Sex**   **Weight (kg)**   **Age (years)**   **Height (cm)**   **Smoker status**[a](#tbl1fna){ref-type="table-fn"}   **Sequence of administration**[b](#tbl1fnb){ref-type="table-fn"}
  ----------------- --------- ----------------- ----------------- ----------------- ----------------------------------------------------- ------------------------------------------------------------------
  **1**             Female    66                49                165               NS                                                    RT
  **2**             Female    70                37                170               NS                                                    RT
  **3**             Female    70                20                164               NS                                                    TR
  **4**             Female    56                19                160               NS                                                    TR
  **5**             Female    61                20                168               NS                                                    TR
  **6**             Female    60                20                160               S                                                     RT
  **7**             Female    63                26                161               NS                                                    RT
  **8**             Female    65                35                174               S                                                     TR
  **9**             Male      85                35                184               S                                                     RT
  **10**            Male      93                28                181               NS                                                    RT
  **11**            Male      74                23                181               NS                                                    TR
  **12**            Male      76                20                174               NS                                                    TR
  **13**            Male      106               46                167               S                                                     TR
  **14**            Male      110               22                181               NS                                                    RT
  **15**            Male      74                18                173               NS                                                    TR
  **16**            Male      70                49                165               NS                                                    RT

NS: non-smoker; S: smoker.

TR: Test-Reference; RT: Reference-Test.
